Recently, the therapeutic effects of small compounds on the inhibition of the PI3K/AKT/mTOR signaling pathway for venous malformation, lymphatic malformations (LMs), and PROS with PIK3CA mutants have been reported [32–34]. The gene discussed is AKT1; the disease is lymphatic malformation.